Skip to main content
. 2016 Nov 14;38(2):233–240. doi: 10.1038/aps.2016.107

Figure 3.

Figure 3

Pharmacokinetic analysis of afatinib in the PC-9 brain metastasis model. (A) Concentrations of afatinib against time in blood and cerebral spinal fluid (CSF); samples were collected 0.5, 2, 8, and 24 h after the administration of 30 mg/kg afatinib (n=3/time point). (B) Ratio of afatinib exposure in CSF and plasma 0.5, 2, 8, and 24 h after the administration of 30 mg/kg afatinib. Mean±SEM.